GLPwatch

Clinical experience with exenatide in a routine secondary care diabetes clinic.

Prim Care Diabetes · 2010

Last updated 2026-05-28

In a study of 90 patients with type 2 diabetes, those who started taking exenatide had an average weight of 114.9 kg and blood sugar control (measured by HbA1c) of 10.3% at the start. After 3 months, their average weight dropped to 108.0 kg and blood sugar control improved to 9.0%. At 6 months, weight was 109.2 kg and blood sugar control was 9.5%.

AI summary of the abstract below.

JournalPrim Care Diabetes, 2010
Citations2
Relative citation ratio0.06
NIH percentile5
Molecules exenatide
Conditions studied Type 2 Diabetes

Abstract

Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA(1c) were 114.9+/-20.6 kg, 10.3+/-2.1% at initiation; 108.0+/-15.3 kg (p<0.0001), 9.0+/-2.1% (p<0.001) at 3 months; 109.2+/-18.2 kg (p<0.0001), 9.5+/-2.3% (p=0.08) at 6 months. Exenatide appears effective in reducing HBA(1c) and weight.

Verbatim abstract via PubMed 20022310 ↗

Related research